RGDXQ (Response Genetics) FCF Margin %: 0.00% (As of Dec. 2015)


What is Response Genetics FCF Margin %?

Response Genetics RGDXQ -98.00% FCF Margin % is 0.00% as of Dec. 2015.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Response Genetics's Free Cash Flow for the three months ended in Dec. 2015 was $0.00 Mil. Response Genetics's Revenue for the three months ended in Dec. 2015 was $0.00 Mil. Therefore, Response Genetics's FCF Margin % for the quarter that ended in Dec. 2015 was 0.00%.

As of today, Response Genetics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Response Genetics's FCF Margin % or its related term are showing as below:

RGDXQ' s FCF Margin % Range Over the Past 10 Years
Min: -124.66   Med: 0   Max: 0
Current: -124.66

RGDXQ's FCF Margin % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -1.8 vs RGDXQ: -124.66

Response Genetics FCF Margin % Related Terms

Response Genetics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Response Genetics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics FCF Margin % Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.18 -47.86 -127.44 -135.72 -81.73

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.48 -95.25 130.02 -49.64 0.00

RGDXQ vs PSID, GBSN, ETAH: FCF Margin % Comparison

For the Diagnostics & Research subindustry, Response Genetics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Genetics FCF Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Response Genetics's FCF Margin % falls into.


Response Genetics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Response Genetics's FCF Margin for the fiscal year that ended in Dec. 2015 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2015 )/Revenue (A: Dec. 2015 )
=-14.744/18.04
=-81.73 %

Response Genetics's FCF Margin for the quarter that ended in Dec. 2015 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2015 )/Revenue (Q: Dec. 2015 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Response Genetics (RGDXQ) has a FCF Margin % of 0.00% as of Dec. 2015. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Response Genetics and its competitors.
Is Response Genetics' FCF Margin % too high?
Response Genetics' current FCF Margin % is 0.00%.
How does Response Genetics' FCF Margin % compare to PSID and GBSN?
Response Genetics' FCF Margin % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Response Genetics and its competitors. Response Genetics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current FCF Margin % is 0.00% as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.